LT3411021T - Sakubitrilo ir valsartano derinio naujas panaudojimas - Google Patents

Sakubitrilo ir valsartano derinio naujas panaudojimas

Info

Publication number
LT3411021T
LT3411021T LTEPPCT/IB2017/050573T LTIB2017050573T LT3411021T LT 3411021 T LT3411021 T LT 3411021T LT IB2017050573 T LTIB2017050573 T LT IB2017050573T LT 3411021 T LT3411021 T LT 3411021T
Authority
LT
Lithuania
Prior art keywords
sacubitrile
valsartan
combination
new use
new
Prior art date
Application number
LTEPPCT/IB2017/050573T
Other languages
English (en)
Inventor
Fabian CHEN
Surya Prakash AYALASOMAYAJULA
Christopher Bush
Masha BERKHIN
Gesine Winzenburg
Bernd TRUEBY
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3411021(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3411021T publication Critical patent/LT3411021T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/IB2017/050573T 2016-02-03 2017-02-02 Sakubitrilo ir valsartano derinio naujas panaudojimas LT3411021T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16154153 2016-02-03
US201662293005P 2016-02-09 2016-02-09
US201662393163P 2016-09-12 2016-09-12
PCT/IB2017/050573 WO2017134600A1 (en) 2016-02-03 2017-02-02 New use of a combination of sacubitril and valsartan

Publications (1)

Publication Number Publication Date
LT3411021T true LT3411021T (lt) 2025-08-25

Family

ID=55299378

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2017/050573T LT3411021T (lt) 2016-02-03 2017-02-02 Sakubitrilo ir valsartano derinio naujas panaudojimas

Country Status (19)

Country Link
US (3) US20190054069A1 (lt)
EP (3) EP4609912A3 (lt)
JP (4) JP7156945B2 (lt)
KR (1) KR102805176B1 (lt)
CN (1) CN108601741B (lt)
AU (2) AU2017215530B2 (lt)
CA (1) CA3010778C (lt)
DK (1) DK3411021T3 (lt)
ES (1) ES3036922T3 (lt)
FI (1) FI3411021T3 (lt)
HR (1) HRP20250913T1 (lt)
HU (1) HUE072182T2 (lt)
IL (1) IL260955A (lt)
LT (1) LT3411021T (lt)
PL (1) PL3411021T3 (lt)
PT (1) PT3411021T (lt)
RS (1) RS67127B1 (lt)
SI (1) SI3411021T1 (lt)
WO (2) WO2017134600A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
WO2019073062A1 (en) * 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
EP3840746A1 (en) * 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2021172960A1 (ko) * 2020-02-26 2021-09-02 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR102545274B1 (ko) * 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
KR20220091767A (ko) * 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
US20240100088A1 (en) * 2021-01-31 2024-03-28 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023284724A1 (zh) * 2021-07-12 2023-01-19 上海博志研新药物技术有限公司 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用
CN116687921B (zh) * 2023-06-14 2026-08-11 宁波大学 沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
EP1416922A1 (en) 2001-07-16 2004-05-12 AstraZeneca AB Pharmaceutical formulation comprising a proton pump inhibitor and antacids
DE60315795T2 (de) 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR101589317B1 (ko) 2007-11-06 2016-01-28 노파르티스 아게 안지오텐신 수용체 길항제/차단제 (arb) 및 중성 엔도펩티다제 (nep) 억제제의 초구조에 기초한 이중-작용 제약 조성물
TWI468191B (zh) 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
CN103079554A (zh) 2010-08-24 2013-05-01 诺华有限公司 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
DK3626270T3 (da) 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤

Also Published As

Publication number Publication date
SI3411021T1 (sl) 2025-09-30
AU2017215530A1 (en) 2018-07-26
EP3411021B1 (en) 2025-05-14
JP7156945B2 (ja) 2022-10-19
EP4609912A3 (en) 2025-11-12
JP6810152B2 (ja) 2021-01-06
AU2017215530B2 (en) 2019-09-12
RS67127B1 (sr) 2025-09-30
EP3411021A1 (en) 2018-12-12
US20240207227A1 (en) 2024-06-27
US20190054069A1 (en) 2019-02-21
JP2024160386A (ja) 2024-11-13
JP2019504096A (ja) 2019-02-14
HRP20250913T1 (hr) 2025-09-26
PT3411021T (pt) 2025-08-06
US20250325518A1 (en) 2025-10-23
PL3411021T3 (pl) 2025-09-08
JP2019504094A (ja) 2019-02-14
CN108601741A (zh) 2018-09-28
AU2019280026A1 (en) 2020-01-16
CA3010778C (en) 2024-02-27
CA3010778A1 (en) 2017-08-10
EP4609912A2 (en) 2025-09-03
DK3411021T3 (da) 2025-08-18
IL260955A (en) 2018-09-20
EP3411018A1 (en) 2018-12-12
HUE072182T2 (hu) 2025-10-28
KR20180103940A (ko) 2018-09-19
CN108601741B (zh) 2022-05-24
WO2017134600A1 (en) 2017-08-10
AU2019280026B2 (en) 2021-09-02
ES3036922T3 (en) 2025-09-25
WO2017134597A1 (en) 2017-08-10
KR102805176B1 (ko) 2025-05-12
JP2023021991A (ja) 2023-02-14
FI3411021T3 (fi) 2025-07-31

Similar Documents

Publication Publication Date Title
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
IL261035A (en) Sulfonylureas, compounds close to them and their uses
LT3283107T (lt) Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3105253T (lt) Antikūnai prieš jagged1 ir jų naudojimo būdai
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
EP3532092A4 (en) IMMUNOGLOBULINS AND USES THEREOF
IL264813B (en) 2-oxo-imidazopyridines and their use
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
EP3102429C0 (en) ROLLING DEVICE, FURNITURE COMPRISING A ROLLING DEVICE AND USE OF THE ROLLING DEVICE
PT3411021T (pt) Nova utilização de uma combinação de sacubitril e valsartan
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
PT3543240T (pt) Inibidor de urat1 e utilização deste
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai
LT3197898T (lt) Nauji imidazopiridazino junginiai ir jų panaudojimas
LT3337506T (lt) Deriniai ir jų panaudojimas
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
GB201617064D0 (en) Compounds and their therapeutic use
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
LT3247711T (lt) Naujos scy-078 druskos ir polimorfai
LT3573611T (lt) Amidų junginiai ir jų naudojimas
LT3512849T (lt) 7-pakeistieji 1-aril-naftiridin-3-karboksamidai ir jų naudojimas
GB201421381D0 (en) A nematicidal composition and the use thereof
GB2533082C (en) A nematicidal composition and the use thereof